Related Experiment Video
Updated: May 26, 2026

Intralymphatic Immunotherapy and Vaccination in Mice
Published on: February 2, 2014
Subcutaneous immunoglobulin replacement therapy with Hizentra® is safe and effective in two infants
Joel L Gallagher1, Niraj C Patel
1Department of Pediatrics, Carolinas Medical Center, Levine Children's Hospital, Charlotte, NC 28232, USA.
Abstract:
Hizentra® is a 20% liquid IgG product approved for subcutaneous administration in adults and children greater than 2 years of age. We report two infants less than 2 years in which administration of Hizentra® was safe and effective.
More Related Videos
08:04Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
Published on: July 9, 2014
16:56Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections
Published on: August 30, 2014
Related Concept Videos
Development of Immunocompetence
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Transcytosis of IgG
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
Humoral Immune Responses
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...